Conventional type 1 dendritic cells (cDC1) in cancer immunity - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Biology Direct Année : 2023

Conventional type 1 dendritic cells (cDC1) in cancer immunity

Résumé

Abstract Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses. Among the distinct DC subsets, conventional type 1 dendritic cells (cDC1) have gained prominence due to their unique ability to cross-present antigens and activate cytotoxic T lymphocytes. This review summarizes the distinctive characteristics of cDC1, their pivotal role in anticancer immunity, and the potential applications of cDC1-based strategies in immunotherapy.
Fichier principal
Vignette du fichier
10619282.pdf (1.22 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04596674 , version 1 (31-05-2024)

Identifiants

Citer

Peng Liu, Liwei Zhao, Guido Kroemer, Oliver Kepp. Conventional type 1 dendritic cells (cDC1) in cancer immunity. Biology Direct, 2023, 18 (1), pp.71. ⟨10.1186/s13062-023-00430-5⟩. ⟨hal-04596674⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More